Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STACY L DONLON

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1346403383
CMS profile
333414
Location
TACOMA, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$102,907.93

114 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
EMD Serono, Inc. $53,939.65 47
TG Therapeutics, Inc. $21,151.40 32
GENZYME CORPORATION $12,582.47 12
Genentech USA, Inc. $8,058.44 9
E.R. Squibb & Sons, L.L.C. $5,886.49 3
Celgene Corporation $1,007.40 7
Novartis Pharmaceuticals Corporation $118.33 1
Genentech, Inc. $97.17 1
Amgen Inc. $45.94 1
Biogen, Inc. $20.64 1

Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STACY L DONLON

NPI 1346403383 · CMS profile ID 333414

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

TACOMA, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1346403383?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STACY L DONLON, NPI 1346403383, CMS profile ID 333414. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346403383?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). STACY L DONLON, NPI 1346403383, CMS profile ID 333414. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346403383?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
STACY L DONLON, NPI 1346403383, CMS profile ID 333414, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1346403383?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

114 matching records · $102,907.93 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 114 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–114 of 114.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
EMD Serono, Inc. $26.9503/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236909659 CMS
Celgene Corporation $131.4503/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184852176 CMS
TG Therapeutics, Inc. $147.5403/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226249666 CMS
Genentech USA, Inc. $88.5702/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211592416 CMS
EMD Serono, Inc. $127.2702/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236913840 CMS
E.R. Squibb & Sons, L.L.C. $195.2602/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1184852156 CMS
E.R. Squibb & Sons, L.L.C. $5,260.0001/30/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1184852152 CMS
EMD Serono, Inc. $298.0001/30/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1236868038 CMS
Celgene Corporation $29.9801/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184852164 CMS
Celgene Corporation $64.9601/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184852166 CMS
Celgene Corporation $30.0001/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184852168 CMS
Celgene Corporation $397.0501/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1184852170 CMS
Celgene Corporation $49.9901/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184852188 CMS
Celgene Corporation $303.9701/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1184852172 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $139,344.75 199
PY2020 $59,330.55 91
PY2021 $49,980.62 51
PY2022 $99,518.98 95
PY2023 $80,804.00 73
PY2024 $80,909.84 72
PY2025 $102,907.93 114

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $137,495.41 17
PY2024 Principal investigator $129,573.92 26
PY2023 Principal investigator $63,513.23 21
PY2022 Principal investigator $120,012.65 22
PY2021 Principal investigator $234,721.50 27
PY2020 Principal investigator $125,068.12 14
PY2019 Principal investigator $250,733.99 12

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

17 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $2,250.00 12/15/2025 Covered Recipient Teaching Hospital
Good Samaritan Hospital
A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1226090587
Principal investigator 1 Genentech, Inc. $3,500.00 10/28/2025 Covered Recipient Teaching Hospital
Tacoma General Allenmore Hospital
OCARINA I No dispute reported 06/30/2026 1211556779
Principal investigator 1 Genentech, Inc. $350.00 08/27/2025 Covered Recipient Teaching Hospital
Tacoma General Allenmore Hospital
OCARINA I No dispute reported 06/30/2026 1211556775
Principal investigator 1 EMD Serono, Inc. $1,000.00 07/15/2025 Covered Recipient Teaching Hospital
Tacoma General Allenmore Hospital
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240117795
Principal investigator 1 EMD Serono, Inc. $1,000.00 07/15/2025 Covered Recipient Teaching Hospital
Tacoma General Allenmore Hospital
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240117798
Principal investigator 1 Roche Products Limited $263.00 06/25/2025 Covered Recipient Teaching Hospital
Tacoma General Allenmore Hospital
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211556762
Principal investigator 1 Roche Products Limited $78.90 06/25/2025 Covered Recipient Teaching Hospital
Tacoma General Allenmore Hospital
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211556765
Principal investigator 1 Roche Products Limited $263.00 06/25/2025 Covered Recipient Teaching Hospital
Tacoma General Allenmore Hospital
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211556768
Principal investigator 1 Novartis Pharmaceuticals Corporation $27,260.00 06/03/2025 Non-covered Recipient Entity
MULTICARE INSTITUTE FOR RESEARCH AND INNOVATION
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190310845
Principal investigator 1 Genentech, Inc. $1,564.00 05/27/2025 Covered Recipient Teaching Hospital
Tacoma General Allenmore Hospital
OCARINA I No dispute reported 06/30/2026 1211556771
Principal investigator 1 Novartis Pharmaceuticals Corporation $93,062.51 03/31/2025 Non-covered Recipient Entity
MULTICARE RESEARCH INSTITUTE FOR RESEARCH AND INNOVATION
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190301631
Principal investigator 1 Genentech, Inc. $5,440.00 02/21/2025 Covered Recipient Teaching Hospital
Tacoma General Allenmore Hospital
Ocrevus Subcutaneous Study for Safety and Tolerability No dispute reported 06/30/2026 1211556806
Principal investigator 1 EMD Serono, Inc. $412.00 01/27/2025 Covered Recipient Teaching Hospital
Tacoma General Allenmore Hospital
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240117791
Principal investigator 1 Roche Products Limited $263.00 01/09/2025 Covered Recipient Teaching Hospital
Tacoma General Allenmore Hospital
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211556744
Principal investigator 1 Roche Products Limited $263.00 01/09/2025 Covered Recipient Teaching Hospital
Tacoma General Allenmore Hospital
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211556749
Principal investigator 1 Roche Products Limited $263.00 01/09/2025 Covered Recipient Teaching Hospital
Tacoma General Allenmore Hospital
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211556753
Principal investigator 1 Roche Products Limited $263.00 01/09/2025 Covered Recipient Teaching Hospital
Tacoma General Allenmore Hospital
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211556758